Remove Development Remove DNA Remove Recombinant DNA Technology
article thumbnail

Leading innovators in gene splicing using nucleases for the pharmaceutical industry

Pharmaceutical Technology

110 innovations will shape the pharmaceutical industry According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

article thumbnail

Sanofi/GSK restart COVID-19 vaccine trials after tweaking formulation

pharmaphorum

Sanofi and GlaxoSmithKline are restarting clinical development of their COVID-19 vaccine, which was delayed after hitting a snag late last year. The vaccine is based around an adjuvanted recombinant protein, which will be tested in a new phase 2 study to assess the response including in older adults.

Vaccine 89
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Amivantamab by Johnson & Johnson for Colorectal Cancer: Likelihood of Approval

Pharmaceutical Technology

Amivantamab is under clinical development by Johnson & Johnson and currently in Phase I for Colorectal Cancer. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. It is based on DuoBody technology platform.

article thumbnail

What is the Difference Between Biologics and Biosimilars?

Pharma Packaging Solutions

There are a few common types of biologics, including extracted (taken directly from a living system), semi-synthesized (produced with recombinant DNA technology), vaccines, and gene therapies. Because biosimilars have a more streamlined development process than biologics, they are typically more affordable.

article thumbnail

Exploring the Miracle Antibody Drug Conjugate Technologies

Roots Analysis

With fourteen approved drugs and several drug candidates being evaluated under different stages of development, antibody drug conjugates (ADCs) are now recognized as a potent class of targeted therapeutics. Over time, a variety of other conjugated therapeutics have also been developed and are under evaluation.

article thumbnail

Beyond the Pill: The Rise of Biologics and the Evolution of Pharmaceutical Therapies

Cloudbyz

Unlike traditional small molecule drugs, which are chemically synthesized, biologics are produced through complex biotechnological processes, often involving recombinant DNA technology. Understanding Biologics: Biologics are a class of therapeutic agents derived from living organisms, such as cells, tissues, or proteins.

Gene 99
article thumbnail

The Importance of Hazard Communications in Clinical Trials Involving Genetic Engineering

Advarra

Recombinant DNA technologies and genetically modified biological agents are being adapted for a wide scope of therapeutic applications, and their use is becoming increasingly common in clinical trials. This is why using an externally administered IBC is paramount for the development of medical recombinant therapeutics.